Details for New Drug Application (NDA): 021492
✉ Email this page to a colleague
NDA 021492 describes ELOXATIN, which is a drug marketed by Sanofi Aventis Us and is included in two NDAs. It is available from one supplier. Additional details are available on the ELOXATIN profile page.
The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
Summary for 021492
| Tradename: | ELOXATIN |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | oxaliplatin |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 9, 2002 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 9, 2002 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
